Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421575 · ClinicalTrials.gov registry record · Early Phase 1
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT02421575: Clinical Trial Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
NCT02421575 is a Early Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 4 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02421575, a Early Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow cancer cells to survive damage from chemotherapy. Hydroxychloroquine may block this process from happening.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-02-26 |
| Phase | Early Phase 1 |
Why NCT02421575 stopped before completion
NCT02421575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02421575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02421575 about?
NCT02421575 is a clinical study titled "Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance". This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow c...
What is the current status of trial NCT02421575?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2016-02-26.
What interventions are being tested in trial NCT02421575?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT02421575?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02421575's enrollment target sits among peer trials
4 1921st of 2000 higher than 53 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia